MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma

Trial Profile

MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refractory asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Mepolizumab (Primary) ; Mepolizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms MENSA
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 May 2017 Results of a post-hoc analysis assessing asthma control in patients treated with SC Mepolizumab/placebo (n=385), presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results of post-hoc analysis presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results of a post-hoc sub-group analyses assessing the impact of mepolizumab on exacerbations in patients who had clinical features of COPD in two phase III trials (DREAM and MENSA), presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top